ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
25 announcements with these filters
Advanced Enzyme Technologies Ltd bought back 50,000 equity shares on September 25, 2026. This transaction was executed at an average price of ₹295.80 per share.
Advanced Enzyme Technologies bought back 64,668 shares on September 24, 2026, at an average price of ₹298.0272 per share.
Advanced Enzyme Technologies bought back 63,616 shares at an average price of ₹297.47. The total value of today's buyback transaction is ₹1.89 Crore.
Advanced Enzyme Technologies Ltd repurchased 1,136 equity shares on September 22, 2026, at an average price of ₹295.90. This daily filing is for compliance.
Advanced Enzyme Technologies bought back 50,000 equity shares on September 21, 2026, at an average price of ₹289.49 per share.
Advanced Enzyme Technologies received requests from four promoter group members to reclassify as 'Public' shareholders. These requests are pending board consideration.
Advanced Enzyme Technologies Ltd reported the daily buyback of 56,066 equity shares on September 17, 2026, at an average price of ₹289.48.
Advanced Enzyme Technologies bought back 55,665 shares on September 16, 2026, at an average price of ₹291.25 per share. Total cumulative buyback stands at 1,297,422 shares.
Advanced Enzyme Technologies bought back 53,607 shares on September 15, 2026, at an average price of ₹294.6372 per share, totaling approximately ₹1.58 Crore.
Advanced Enzyme Technologies bought 46,212 shares on September 09, 2026, at an average price of ₹299.5388 per share as part of its ongoing buyback programme.
Advanced Enzyme Technologies Ltd bought back 36,543 shares at an average price of ₹299.4999 on September 08, 2026, under its ongoing buyback program.
Advanced Enzyme Technologies extinguished 8,25,028 equity shares (face value ₹2) bought back in August 2026. The certificate confirms compliance with SEBI Buy-Back Regulations.
Advanced Enzyme Technologies Ltd reported the buyback of 31,197 equity shares on September 07, 2026. The average acquisition price was ₹295.9121 per share.
Advanced Enzyme Technologies received requests from five promoter group members to reclassify from 'Promoter Group' to 'Public' category under SEBI Regulation 31A.
Advanced Enzyme Technologies bought back 55,332 shares on September 04, 2026, at an average price of ₹297.9337 per share under its buyback program.
Advanced Enzyme Technologies bought back 31,571 equity shares at an average price of ₹295.39 per share, totaling ₹0.93 Crore on September 03, 2026.
Advanced Enzyme Technologies bought back 58,083 equity shares on September 02, 2026, at an average price of ₹295.3153 per share, totaling 9,41,885 cumulative shares.
Q1FY27 was muted with flat revenue growth and EBITDA contraction due to higher energy costs and standard revenue reversal accounting. Management maintains double-digit growth targets despite current geopolitical and US-market headwinds.
Advanced Enzyme reported Q1 FY27 revenue of ₹1,898 mn, up 2% YoY, despite a 10% EBITDA decline. Segment performance was mixed, with specialized manufacturing and bio-processing showing strong growth.
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹189.8 Cr (+2.1% YoY) and net profit of ₹38.6 Cr (-4.5% YoY) for Q1 FY27.
Advanced Enzyme reported its highest-ever quarterly and annual revenue for FY26. Management focused on expanding R&D, human healthcare flagship growth, and navigating global supply chain disruptions.
Advanced Enzyme delivered its highest ever quarterly revenue with robust double-digit growth across all segments. However, management remains cautious about global inflationary pressures on energy and logistics costs potentially impacting near-term margins.
Advanced Enzyme reported strong FY26 performance with 17% revenue growth and 30% PAT growth, driven by Human and Animal Nutrition segments and record margins.
Advanced Enzyme reported strong Q4FY26 results with 22% YoY revenue growth and 69% YoY PAT growth. Focus remains on expanding human and animal nutrition segments globally.
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹203.4 Cr (+21.7% YoY) and net profit of ₹45.3 Cr (+69.7% YoY) for Q4 FY26.